These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28351696)

  • 1. Editorial commentary: New drugs for diabetes: Finally safety and cardiovascular efficacy.
    Connelly KA
    Trends Cardiovasc Med; 2017 Jul; 27(5):376-377. PubMed ID: 28351696
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
    Forst T; Plum-Mörschel L; Weber MM
    Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular safety of new type 2 diabetes drugs].
    Hormigo Pozo A; Mancera Romero J
    Semergen; 2014 Mar; 40(2):55-6. PubMed ID: 24655909
    [No Abstract]   [Full Text] [Related]  

  • 5. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs.
    Turner JR; Caveney E; Gillespie BS; Karnad DR; Kothari S; Metz A; Keller LH
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):75-76. PubMed ID: 28122792
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus.
    Menon V; Lincoff AM
    Circulation; 2014 Jun; 129(25):2705-13. PubMed ID: 24958753
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of diabetes: Crossing to the other side.
    Skliros NP; Vlachopoulos C; Tousoulis D
    Hellenic J Cardiol; 2016; 57(5):304-310. PubMed ID: 27687958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk].
    Kern A; Zaleska M; Możeńska O; Bil J
    Wiad Lek; 2017; 70(4):827-833. PubMed ID: 29064812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.
    Singh S
    Curr Diab Rep; 2014 Dec; 14(12):563. PubMed ID: 25363547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of type 2 diabetes: what's new in 2017?
    Scheen AJ
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1383-1394. PubMed ID: 28879786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regarding "cardiovascular complications of diabetes" editorial article Can J Diabetes; 37(5); (2013), 279-281.
    Snyman ER
    Can J Diabetes; 2014 Feb; 38(1):3. PubMed ID: 24485203
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs and diabetes: understanding the new breed of cardiovascular safety trials.
    Adler AI
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):175-7. PubMed ID: 24622361
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiovascular safety concerns of glucose-lowering drugs].
    Scholze J
    MMW Fortschr Med; 2017 Jan; 159(1):62-66. PubMed ID: 28097552
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
    Xu J; Rajaratnam R
    Cardiovasc Diabetol; 2017 Feb; 16(1):18. PubMed ID: 28148253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?
    Doggrell SA
    Expert Opin Drug Saf; 2015 Jun; 14(6):801-5. PubMed ID: 25891299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?].
    Mannucci E
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetes medications and cardiovascular outcome trials: Lessons learned.
    Patel KV; de Albuquerque Rocha N; McGuire DK
    Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.